FDA plans risk communication review

Share this article:
A significant effort by FDA is now in "the planning stage," designed to determine how patients, physicians and other healthcare providers obtain information about emerging risks associated with drugs and medical devices, according to Nancy Ostrove, Office of the Commissioner senior advisor for risk communication.

Speaking at a workshop on risk communication in Bethesda, MD, Ostrove said the research study is expected to yield "quantitative as well as qualitative data" on how patients and providers get risk information, as well as their perceptions concerning various formats and means of distribution of public health advisories. The study will include a national survey of providers, and focus groups comprised of patients and consumers.

The need for research to help guide FDA's future risk communication efforts was revealed by the results of a public hearing on the subject, held last December, Ostrove said. Testimony at the hearing criticized the agency's Web site as "too complex" and "difficult to navigate."

More recently, Ostrove said a study of indicated physicians and pharmacists believe that learning about product risks through the popular media (press, television), while rapid, is often simplified, one-sided and unreliable. Information from professional sources (meetings, newsletters, journals) was generally viewed as credible and objective.

While information received from FDA was generally viewed as credible it was often "slower than from other sources"—in some cases even slower than information acquired from professional journals.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.